XOMA Corp. has earned a $2 million milestone payment from Takeda Pharmaceutical Company as the first patient has been dosed in its Phase 2 study to evaluate safety, tolerability, and efficacy of mezagitamab (TAK-079) in generalized myasthenia gravis.